VIA
CNTB

Vident Investment Advisory’s Connect Biopharma Holdings CNTB Stock Holding History

Vident Investment Advisory’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18,062
Closed -$16K – 1149
2022
Q2 		$16K Hold
18,062
– – ﹤0.01% 1258
2022
Q1 		$55K Buy
+18,062
New +$76.2K ﹤0.01% 1245
2021
Q4 		– Sell
-10,851
Closed -$263K – 1209
2021
Q3 		$263K Buy
+10,851
New +$246K 0.01% 1031

Other funds holding CNTB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vident Investment Advisory's CNTB Position: Q3 2022 in Review

Vident Investment Advisory sold out of Connect Biopharma Holdings (CNTB) in Q3 2022, closing a stake of 18,062 shares — an estimated $16K sold.

Vident Investment Advisory first reported a position in CNTB in Q3 2021 and held it in 3 quarters. The position peaked at $263K in Q3 2021. 25 funds tracked by Wall St. Rank hold CNTB as of Q3 2022.

  • Vident Investment Advisory reported no remaining Connect Biopharma Holdings position as of Q3 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 18,062 Connect Biopharma Holdings shares in Q3 2022, an estimated $16K.
  • Vident Investment Advisory first reported a position in Connect Biopharma Holdings in Q3 2021 and held it in 3 quarters.
  • Vident Investment Advisory's Connect Biopharma Holdings position peaked at $263K in Q3 2021.
  • 25 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q3 2022.

Based on Vident Investment Advisory's 13F filing for Q3 2022, filed 14 Nov 2022.